| Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight I Singh, C Morgan, V Curran, D Nutt, A Schlag, R McShane The Lancet Psychiatry 4 (5), 419-426, 2017 | 140 | 2017 |
| Adverse effects of psychedelics: From anecdotes and misinformation to systematic science AK Schlag, J Aday, I Salam, JC Neill, DJ Nutt Journal of Psychopharmacology 36 (3), 258-272, 2022 | 137 | 2022 |
| Europeans and aquaculture: perceived differences between wild and farmed fish A Katrin Schlag, K Ystgaard British Food Journal 115 (2), 209-222, 2013 | 98 | 2013 |
| Aquaculture: an emerging issue for public concern AK Schlag Journal of Risk Research 13 (7), 829-844, 2010 | 92 | 2010 |
| A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation O Rogeberg, D Bergsvik, LD Phillips, J Van Amsterdam, N Eastwood, ... International Journal of Drug Policy 56, 144-152, 2018 | 56 | 2018 |
| Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics AK Schlag, SE O'Sullivan, RR Zafar, DJ Nutt Neuropharmacology 191, 108586, 2021 | 53 | 2021 |
| Percentages of problem drug use and their implications for policy making: A review of the literature AK Schlag Drug Science, Policy and Law 6, 2050324520904540, 2020 | 51 | 2020 |
| An evaluation of regulatory regimes of medical cannabis: what lessons can be learned for the UK? AK Schlag Medical Cannabis and Cannabinoids 3 (1), 76-83, 2020 | 50 | 2020 |
| Aquaculture in Europe: media representations as a proxy for public opinion AK Schlag International Journal of Fisheries and Aquaculture 3 (7), 158-165, 2011 | 48 | 2011 |
| So near yet so far: why won’t the UK prescribe medical cannabis? D Nutt, S Bazire, LD Phillips, AK Schlag BMJ open 10 (9), e038687, 2020 | 47 | 2020 |
| Medical cannabis in the UK: From principle to practice AK Schlag, DS Baldwin, M Barnes, S Bazire, R Coathup, HV Curran, ... Journal of Psychopharmacology 34 (9), 931-937, 2020 | 36 | 2020 |
| A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products DJ Nutt, LD Phillips, MP Barnes, B Brander, HV Curran, A Fayaz, DP Finn, ... Cannabis and cannabinoid research 7 (4), 482-500, 2022 | 34 | 2022 |
| Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21 C Sakal, M Lynskey, AK Schlag, DJ Nutt Psychopharmacology 239 (5), 1147-1155, 2022 | 32 | 2022 |
| Cannabis based medicines and cannabis dependence: A critical review of issues and evidence AK Schlag, C Hindocha, R Zafar, DJ Nutt, HV Curran Journal of Psychopharmacology 35 (7), 773-785, 2021 | 32 | 2021 |
| Risk-risk tradeoffs: what should we do in Europe? R Lofstedt, A Schlag Journal of Risk Research 20 (8), 963-983, 2017 | 28 | 2017 |
| Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research SL Bourke, AK Schlag, SE O'Sullivan, DJ Nutt, DP Finn Pharmacology & therapeutics 240, 108216, 2022 | 24 | 2022 |
| The value of real world evidence: The case of medical cannabis AK Schlag, RR Zafar, MT Lynskey, LD Phillips, DJ Nutt Frontiers in Psychiatry 13, 1027159, 2022 | 20 | 2022 |
| Ending the pain of children with severe epilepsy? an audit of the impact of medical cannabis in 10 patients RR Zafar, AK Schlag, DJ Nutt Drug Science, Policy and Law 6, 2050324520974487, 2020 | 13 | 2020 |
| Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: evidence from project twenty 21 AK Schlag, M Lynskey, A Fayaz, A Athanasiou-Fragkouli, B Brandner, ... Frontiers in Pain Research 3, 891498, 2022 | 12 | 2022 |
| A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use S Rolles, AK Schlag, F Measham, L Phillips, D Nutt, D Bergsvik, ... International Journal of Drug Policy 91, 103180, 2021 | 12 | 2021 |
